The mission of the Southwest Oncology Group (SWOG) is to conduct clinical trials to prevent and treat cancer in adults, and to improve the quality of life for cancer survivors. The mission is accomplished through the mutual efforts ofthe Group Chair's Office, the Operations Office, the Statistical Center and the dedicated oncology professionals in the institutions of the Group. The Statistical Center contributes to the mission of the Group though the following key activities: 1) Participation in protocol development, emphasizing statistically sound study designs;2) Collection, review, manage and store data from Group studies, and to follow sound quality control procedures which ensure the integrity of data evaluations;3) Development and maintenance of electronic applications to support the research and goals of the Southwest Oncology Group, including data collection, data management, data retrieval and analysis;4) Analysis, interpretation and publication of results from ail Southwest Oncology Group studies;5) Performance of methodologic research to address ongoing design and analysis issues important to the conduct of cancer clinical trials and to ancillary biologic studies;6) Participation in training of new Clinical Research Associates (CRAs) and of Young Investigators in the Group. Biostatisticians and Data Coordinators educate investigators, nurse oncologists and CRAs in statistical analysis, research design and the utilization of the most advanced scientific and data management strategies;and 7) Collaboration with the Group Chair and other investigators in the Group to improve the quality of clinical trials through the use of improved data collection forms, reproducible data definitions and economical data flow, and efficient use of Statistical Center resources.
Clinical trials are the best mechanism for improving the outcomes of therapy for cancer, increasing the chance for cure and the probability that future patients will be given appropriate care. The SWOG Statistical Center contributes to this process through the efficient and high-quality design, management, and analysis of these trials, thereby helping to ensure that the results of clinical trials are generalizable and reproducible.
|West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92|
|Dai, James Y; Liang, C Jason; LeBlanc, Michael et al. (2018) Case-only approach to identifying markers predicting treatment effects on the relative risk scale. Biometrics 74:753-763|
|Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585|
|Sala Torra, Olga; Othus, Megan; Williamson, David W et al. (2017) Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients. Biol Blood Marrow Transplant 23:691-696|
|Unger, Joseph M; Griffin, Katherine; Donaldson, Gary W et al. (2017) Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). J Patient Rep Outcomes 2:27|
|Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641|
|Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40|
|Lara Jr, Primo N; Moon, James; Redman, Mary W et al. (2016) Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer 17:113-8.e1-2|
|Othus, M; Mukherjee, S; Sekeres, M A et al. (2016) Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course. Leukemia 30:1779-80|
|Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7|
Showing the most recent 10 out of 512 publications